Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Actemra, Enbrel, Rituxan Study Suggests Significant Differences Between Clinical Trials, Real World December 4, 2017 Irvin Jackson Add Your Comments A new study looking at the side effects of Actemra and other rheumatoid arthritis drugs challenges conventional wisdom that randomized clinical trials, considered the gold standard of drug and medical device studies, are more revealing than observational studies. Researchers at the Institute of Social and Preventative Medicine (ISPM) at the University of Bern in Switzerland published a study last month in the medical journal Rheumatology, comparing the two techniques as they have been applied to Actemra, Enbrel and Rituxan; all drugs used to treat rheumatoid arthritis (RA), and found observational studies may better reflect the real-world effectiveness of such drugs. Randomized clinical trials (RCTs) involve taking groups of test subjects and giving some the active ingredient and others a placebo which has no actual active ingredient and looking at the differences in efficacy and safety. They are usually “blind” meaning that even the doctors administering the drugs are unaware of whether they are giving patients the actual drug or the placebo. Observational studies collect data on the drugs’ use in real world settings. Learn More About Actemra Lawsuits Heart attacks, strokes, heart failure, lung disease, pancreatitis and other injuries linked to Actemra. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Actemra Lawsuits Heart attacks, strokes, heart failure, lung disease, pancreatitis and other injuries linked to Actemra. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Researchers conducted systematic literature reviews of randomized clinical trials and observational studies, comparing the data and whether baseline characteristics changed over time. They found a number of differences in the observational studies once the drugs were in use when compared to the randomized clinical trials that preceded their release to the market. According to the findings, when looking at Actemra and similar drugs, observational studies revealed that the typical patient was three years older than assumed in the clinical trials, had taken 1.6 more drugs previously to treat their condition than the clinical trials predicted, and other differences which could result in safety and effectiveness differences than those found during the clinical trials. “There are substantial systematic differences in patient characteristics between RCTs and registries in RA,” the researchers concluded. “The efficacy seen in RCTs may not reflect real-world effectiveness.” Actemra Health Concerns The findings come as a growing number of individuals nationwide are reviewing potential Actemra lawsuits, as questions have emerged about serious risks associated with the medication that are not adequately disclosed on the label warnings. Actemra (tocilizumab) was introduced in 2010, as a second-line treatment for rheumatoid arthritis, in severe cases where individuals have not responded to other drugs. In May 2017, the FDA approved expanded use to treat giant cell arteritis, and the medication has grown to generate over $1.6 billion in annual sales. Unlike other competing rheumatoid arthritis drugs, Actemra warnings do not include information about certain health risks linked to competing treatments, such as Humira, Remicade and Enbrel. Therefore, many doctors and consumers are under the impression that Actemra is safer. However, recent reports suggest that users may face the same, or higher risks. A recent independent review of adverse event reports submitted to the FDA identified a higher-than-expected number of severe injuries, including heart attacks, strokes, heart failure, interstitial lung disease and pancreatitis. In addition, the drug has been linked to at least 1,128 deaths since 2010. As a result, some are calling for Actemra warnings to be added, which may cut into sales. According to allegations being investigated against the drug maker, evidence suggests that Roche knew or should have known that the drug carried similar risks to other rheumatoid arthritis drugs, but withheld information from the label to create a false impression that their drug was safer. Tags: Actemra, Arthritis, Clinical Trials, Enbrel, Rheumatoid Arthritis, Rituxan More Actemra Lawsuit Stories Amid Concerns About Actemra Health Problems, FDA Approves Drug For Juvenile Arthritis Treatment September 27, 2018 Actemra Side Effects Increase Risk Of Blood Loss After Knee Replacement Surgery: Study January 17, 2018 Actemra Unfit For Use Against Giant Cell Arthritis, UK Regulators Rule December 11, 2017 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025) Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025) Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)
Amid Concerns About Actemra Health Problems, FDA Approves Drug For Juvenile Arthritis Treatment September 27, 2018
Actemra Side Effects Increase Risk Of Blood Loss After Knee Replacement Surgery: Study January 17, 2018
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)
Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)